Assessment of the low dose oral minoxidil in the post hair transplant treatment

Evaluating the efficacy of low dose oral minoxidil Post Hair Transplant, in patterned hair loss: A Prospective Study - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/03/063787

Enrollment

Registered

2024-03-07

Start date

Unknown

Completion date

Unknown

Last updated

2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L649- Androgenic alopecia, unspecified

Interventions

Intervention1: Oral Minoxidil: 0.25mg followed by 0.5mg tab: First week 0.25-tab followed by 0.5 tab for a week followed by 1 tab for a week and continue to 6 months Control Intervention1: NA: NA

Eligibility

Inclusion criteria

Inclusion criteria: All male patients who undergo hair transplantation following no response to conventional therapies Patient consenting for study

Exclusion criteria

Exclusion criteria: Patient with history of cardio vascular diseases Patients with chronic renal diseases Patient with history of hypotension Patient taking medications like aspirin, blood thinners and guanethidine

Design outcomes

Primary

Measure	Time frame
To evaluate the efficacy of oral minoxidil in post hair transplantation patients. To assess the safety and adverse effects associated low dose oral minoxidil. To evaluate patient satisfaction and subjective perceptions of treatment outcome.Timepoint: After 6 months	—

Secondary

Measure	Time frame
Efficacy will be evaluated by hair counts, hair diameter measurements, anagen telogen ratio photographic assessment by trichoscanTimepoint: After 6 months	—

Countries

India

Contacts

Public ContactDr Megha C

CUTIS Academy of Cutaneous Sciences

drmeghacs@gmail.com8095196167

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026